Assessment of patient-reported outcomes (PROs)

treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea

Dong Won Byun, Seong Hwan Moon, Tak Kim, Hae Hyeog Lee, Hyoung Moo Park, Moo Il Kang, Yong Chan Ha, Ho Yeon Chung, Byung Koo Yoon, Tae Young Kim, Soo Uk Chae, Chan Soo Shin, Kyu Hyun Yang, Jae Hyup Lee, Jae Suk Chang, Sung Hoon Kim, In Joo Kim, Jung Min Koh, Jung Hwa Jung, Kyong Wook Yi & 11 others Jeong Joon Yoo, Dong Jin Chung, Young Kyun Lee, Hyun Koo Yoon, Seongbin Hong, Deog Yoon Kim, Ki Hyun Baek, Hyun Joo Kim, Young Joo Kim, Seongsik Kang, Yong Ki Min

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.

Original languageEnglish
Pages (from-to)563-572
Number of pages10
JournalJournal of Bone and Mineral Metabolism
Volume37
Issue number3
DOIs
StatePublished - 15 May 2019

Fingerprint

Postmenopausal Osteoporosis
Medication Adherence
Korea
Quality of Life
Osteoporosis
Therapeutics
Selective Estrogen Receptor Modulators
Social Adjustment
Patient Reported Outcome Measures
Hormone Replacement Therapy
Diphosphonates
Risk Management
Visual Analog Scale
Tooth
Regression Analysis
Demography

Keywords

  • Gastrointestinal events
  • Medication adherence
  • Postmenopausal osteoporosis
  • Quality of life
  • Treatment satisfaction

Cite this

Byun, Dong Won ; Moon, Seong Hwan ; Kim, Tak ; Lee, Hae Hyeog ; Park, Hyoung Moo ; Kang, Moo Il ; Ha, Yong Chan ; Chung, Ho Yeon ; Yoon, Byung Koo ; Kim, Tae Young ; Chae, Soo Uk ; Shin, Chan Soo ; Yang, Kyu Hyun ; Lee, Jae Hyup ; Chang, Jae Suk ; Kim, Sung Hoon ; Kim, In Joo ; Koh, Jung Min ; Jung, Jung Hwa ; Yi, Kyong Wook ; Yoo, Jeong Joon ; Chung, Dong Jin ; Lee, Young Kyun ; Yoon, Hyun Koo ; Hong, Seongbin ; Kim, Deog Yoon ; Baek, Ki Hyun ; Kim, Hyun Joo ; Kim, Young Joo ; Kang, Seongsik ; Min, Yong Ki. / Assessment of patient-reported outcomes (PROs) : treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. In: Journal of Bone and Mineral Metabolism. 2019 ; Vol. 37, No. 3. pp. 563-572.
@article{c20e4bb3cdb24e68bcf4bc66cfde6f15,
title = "Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea",
abstract = "Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1{\%} used bisphosphonate, with the majority (67.2{\%}) using weekly medication, 27.8{\%} used daily hormone replacement therapy, and 12.1{\%} used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6{\%}) and dental visits due to problems (24.1{\%}) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.",
keywords = "Gastrointestinal events, Medication adherence, Postmenopausal osteoporosis, Quality of life, Treatment satisfaction",
author = "Byun, {Dong Won} and Moon, {Seong Hwan} and Tak Kim and Lee, {Hae Hyeog} and Park, {Hyoung Moo} and Kang, {Moo Il} and Ha, {Yong Chan} and Chung, {Ho Yeon} and Yoon, {Byung Koo} and Kim, {Tae Young} and Chae, {Soo Uk} and Shin, {Chan Soo} and Yang, {Kyu Hyun} and Lee, {Jae Hyup} and Chang, {Jae Suk} and Kim, {Sung Hoon} and Kim, {In Joo} and Koh, {Jung Min} and Jung, {Jung Hwa} and Yi, {Kyong Wook} and Yoo, {Jeong Joon} and Chung, {Dong Jin} and Lee, {Young Kyun} and Yoon, {Hyun Koo} and Seongbin Hong and Kim, {Deog Yoon} and Baek, {Ki Hyun} and Kim, {Hyun Joo} and Kim, {Young Joo} and Seongsik Kang and Min, {Yong Ki}",
year = "2019",
month = "5",
day = "15",
doi = "10.1007/s00774-018-0956-6",
language = "English",
volume = "37",
pages = "563--572",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "3",

}

Byun, DW, Moon, SH, Kim, T, Lee, HH, Park, HM, Kang, MI, Ha, YC, Chung, HY, Yoon, BK, Kim, TY, Chae, SU, Shin, CS, Yang, KH, Lee, JH, Chang, JS, Kim, SH, Kim, IJ, Koh, JM, Jung, JH, Yi, KW, Yoo, JJ, Chung, DJ, Lee, YK, Yoon, HK, Hong, S, Kim, DY, Baek, KH, Kim, HJ, Kim, YJ, Kang, S & Min, YK 2019, 'Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea', Journal of Bone and Mineral Metabolism, vol. 37, no. 3, pp. 563-572. https://doi.org/10.1007/s00774-018-0956-6

Assessment of patient-reported outcomes (PROs) : treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. / Byun, Dong Won; Moon, Seong Hwan; Kim, Tak; Lee, Hae Hyeog; Park, Hyoung Moo; Kang, Moo Il; Ha, Yong Chan; Chung, Ho Yeon; Yoon, Byung Koo; Kim, Tae Young; Chae, Soo Uk; Shin, Chan Soo; Yang, Kyu Hyun; Lee, Jae Hyup; Chang, Jae Suk; Kim, Sung Hoon; Kim, In Joo; Koh, Jung Min; Jung, Jung Hwa; Yi, Kyong Wook; Yoo, Jeong Joon; Chung, Dong Jin; Lee, Young Kyun; Yoon, Hyun Koo; Hong, Seongbin; Kim, Deog Yoon; Baek, Ki Hyun; Kim, Hyun Joo; Kim, Young Joo; Kang, Seongsik; Min, Yong Ki.

In: Journal of Bone and Mineral Metabolism, Vol. 37, No. 3, 15.05.2019, p. 563-572.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Assessment of patient-reported outcomes (PROs)

T2 - treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea

AU - Byun, Dong Won

AU - Moon, Seong Hwan

AU - Kim, Tak

AU - Lee, Hae Hyeog

AU - Park, Hyoung Moo

AU - Kang, Moo Il

AU - Ha, Yong Chan

AU - Chung, Ho Yeon

AU - Yoon, Byung Koo

AU - Kim, Tae Young

AU - Chae, Soo Uk

AU - Shin, Chan Soo

AU - Yang, Kyu Hyun

AU - Lee, Jae Hyup

AU - Chang, Jae Suk

AU - Kim, Sung Hoon

AU - Kim, In Joo

AU - Koh, Jung Min

AU - Jung, Jung Hwa

AU - Yi, Kyong Wook

AU - Yoo, Jeong Joon

AU - Chung, Dong Jin

AU - Lee, Young Kyun

AU - Yoon, Hyun Koo

AU - Hong, Seongbin

AU - Kim, Deog Yoon

AU - Baek, Ki Hyun

AU - Kim, Hyun Joo

AU - Kim, Young Joo

AU - Kang, Seongsik

AU - Min, Yong Ki

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.

AB - Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.

KW - Gastrointestinal events

KW - Medication adherence

KW - Postmenopausal osteoporosis

KW - Quality of life

KW - Treatment satisfaction

UR - http://www.scopus.com/inward/record.url?scp=85053797997&partnerID=8YFLogxK

U2 - 10.1007/s00774-018-0956-6

DO - 10.1007/s00774-018-0956-6

M3 - Article

VL - 37

SP - 563

EP - 572

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 3

ER -